Infliximab for the treatment of orofacial Crohn's disease

被引：57

作者：

Mahadevan, U

Sandborn, WJ

机构：

[1] Mayo Clin, Rochester, MN 55905 USA

[2] Univ Calif San Francisco, Dept Med, Div Gastroenterol & Hepatol, San Francisco, CA 94143 USA

来源：

INFLAMMATORY BOWEL DISEASES | 2001年 / 7卷 / 01期

关键词：

Crohn's disease; orofacial manifestations;

D O I：

10.1097/00054725-200102000-00006

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Orofacial manifestations of Crohn's disease can be difficult to diagnose and treat. We report a case in which the orofacial lesions occurred 7 years prior to the diagnosis of underlying inflammatory bowel disease. The patient was refractory to mesalamine and systemic corticosteroids but responded to infliximab, the chimeric monoclonal antibody to tumor necrosis factor (TNF-alpha). A review of the literature of the orofacial granulomatoses is presented as well.

引用

页码：38 / 42

页数：5

共 28 条

[1]

BASU MK, 1975, GUT, V16, P249

[2]

BOERR LA, 1987, AM J GASTROENTEROL, V82, P1326

[3] Orofacial granulomatosis and Crohn's disease [J].